Fractyl Laboratories Named to Fierce 15 List by FierceMedicalDevices
October 14, 2015
Each year FierceMedicalDevices accepts nominations to seek out the best and most relevant examples of innovative medical device and diagnostic companies. The finalists are chosen based on their potential to advance their medical technology in to a new realm so that it is appealing to physicians, patients and payers throughout the global healthcare community.
Domain Associates has been in integral part in promoting and investing companies that strive to create medical devices that offer a “curative” approach. This emerging trend aims to offer relief from symptoms with only a few visits to the physician and reduce the reliance on daily therapeutics to treat chronic conditions.
This year’s Fierce 15 list is a reflection of this growing medical device space as Domain portfolio company, Fractyl Laboratories, has developed a unique device-based endoscopic procedure that alters the body’s ability to process sugar and dramatically improve glycemic control for patients with type 2 diabetes.
Last year’s Fierce 15 List included three of Domain’s portfolio companies: Astute Medical, NeuroPace, and Oraya Therapeutics. Astute Medical’s NephroCheck test is a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury. Neuropace is a successful example of a medical device that offers relief to those suffering from epilepsy. While Oraya continues to lead the way with novel radiotherapeutic device for treating wet age-related macular degeneration.
Click here for the full list of 2015 Fierce 15 companies
To learn more and read recent news about Fractyl Laboratories click links below: